ARTICLE | Company News
Emmes Corp., NIH cancer news
October 13, 2014 7:00 AM UTC
CRO Emmes said clinical investigators from the AIDS Malignancy Consortium (AMC) began a study to investigate strategies to prevent high-grade squamous intraepithelial lesions (HSIL) from progressing to anal cancer. Emmes is coordinating the trial under an eight-year, $89 million award, and NIH's NCI is funding the trial through a cooperative agreement with University of California, Los Angeles. AMC is a NCI-supported clinical trials group founded in 1995 to support innovative trials for AIDS-associated malignancies. ...